More than 90% of patients with critical coronavirus treated with antimalarial drug hydroxychloroquine seen signs of dangerous heart arrhythmias, showed research conducted in USA and France. These manifested signs can lead to fatal cardiac arrest
Doctors warn that the use of hydroxychloroquine for the treatment of coronavirus can be dangerous, because more than 90 percent of patients with Covid-19 in two studies of the drug showed signs of dangerous heart arrhythmias, writes British newspaper The Daily Mail.
If cardiac arrhythmia is too long, it can cause heart attack and stroke.
Researchers in the United States and France closely monitored the action advertised trump anti-malarial drugs with 90 and 40 patients, respectively.
Each of these studies found that more than 90 percent of patients with coronavirus in intensive care had a longer than usual delay between contractions of the heart, which is a worrying sign that the drug may impair their cardiac function.
The American President trump (and not only he, but many doctors and patients) had high hopes for hydroxychloroquine, once held in France, the study showed that this medication significantly improved the survival rates and healing time for patients with coronavirus.
Managing quality control of products and medicines USA gave permission for the emergency use of hydroxychloroquine for doctors, so they tried to apply the drug to U.S. patients with the coronavirus.
“Among the possible methods of treatment hydroxychloroquine promoted and even politicized as a promising therapy because of its potential anti-inflammatory and antiviral properties,” said a cardiologist at northwestern University Dr. Robert Bono in its editorial in the journal JAMA Cardiology.
But this medicine is not without hidden dangers, notes The Daily Mail. Although it is used to treat malaria and autoimmune diseases such as lupus and rheumatoid arthritis, hydroxychloroquine can lead the process, which causes the heart to beat in time.
One study of this drug in Brazil was stopped after many of the registered patients with the coronavirus, which was treated with hydroxychloroquine developed arrhythmia.
To try to determine when, why and how often this occurred, researchers from Massachusetts General hospital in USA and the University of Lyon in France closely followed the so-called syndromes remote interval (QT) in critical patients with the coronavirus treated with hydroxychloroquine.
In fact, the QT interval measures the time that passes between when the ventricular heart muscle is reduced, and then relaxes.
When this interval becomes too long, the patient had developed a dangerous form of heart arrhythmia (called atrial fibrillation).
This was one of the main reasons why patients are advised to stop taking the drug.
Normal QT interval lasts from 400 to 440 MS (men have shorter QT intervals than females).
In the French study, a quarter of the patients had QT intervals that were conducted in 60 milliseconds longer, and 18% of the observed was recorded intervals with a duration of 500 milliseconds or longer.
In the research of experts from Massachusetts, 20% of the 90 patients had QT levels reaching or exceeding 500 milliseconds. 30 of them were treated in intensive care units.
Special concern stems from the fact that doctors believe that coronavirus can infect the heart and cardiovascular system, infecting tissue causing blood clots damaging the blood vessels or the resulting inflammation caused by a virus.
Dr. Robert Bono noted that acutely ill patients, such as most of those treated in these two studies may be at greater risk of cardiac arrhythmia due to other factors.
He also writes that it is possible that in some cases the potential benefit of hydroxychloroquine may outweigh the risk of arrhythmias.
This is reflected on the website of the American College of cardiology about the experimental use of hydroxychloroquine for the treatment of patients with COVID-19, “Though the use of drugs that prolong QT, is associated with an increased risk of death, this risk may be less than the potential benefit from treatment COVID-19 for some patients. Currently there is hope for the benefits of hydroxychloroquine, but there is little evidence. That could change quickly, given the multiple pending clinical trials”.